The two primary growth drivers are continued global scaling of the GLP-1 franchise and the maturing non-GLP-1 portfolio across oncology, immunology, and neuroscience
331 Teixeira, P
In late 2023, the FDA added more than a dozen peptides including both BPC-157 and thymosin alpha 1 to its list of substances that should not be compounded because the agency has identified potential significant safety risks. For BPC-157, the agency warned that the peptide could trigger an immune response
To mitigate these risks, comprehensive in vitro and in vivo studies evaluating the immunogenic potential of peptide compounds should be conducted before initiating clinical trials
Ex vivo pancreatic islet GSIS assay was performed once with three to four pancreatic islets isolated from different mice
Weekly weigh-ins (same day, same time, same conditions) smooth out some of this noise, but even then, a single week without weight loss does not indicate a problem